title: [Influence of serotonergic transmission on response to olanzapine].
abstract: BACKGROUND
  This study aimed to investigate associations between the response to olanzapine and genetic variations (polymorphisms) in serotonergic transmission related genes in a sample of prospectively studied schizophrenic patients treated with this drug.
  
  
  METHODS
  A total of 51 non-related patients with a DSM-IV diagnosis of schizophrenia were treated with olanzapine (mean dose: 12 mg/day; range: 5-25 mg) and followed-up for at least three months. Response to olanzapine was measured by the difference between baseline and post-treatment scores on the PANSS and GAS scales. The following polymorphisms were studied: serotonin receptor 5-HT2A (102-T/C, His452Tyr), serotonin receptor 5-HT2C (Cys23Ser, -330-GGT/-244-CT), and serotonin transporter (VNTR, 5-HTTLPR).
  
  
  RESULTS
  Global clinical improvement, measured with both the GAS and PANSS total scores, was observed. When patients were divided into responders and non-responders, the distribution of genotypic and allelic frequencies was similar to the one observed in previous studies with clozapine. When regression analyses were undertaken, polymorphism 330-GT/-244-CT of the 5-HT2C serotonin receptor and 5-HTTLPR of the serotonin transporter showed a tendency towards the association to olanzapine response.
  
  
  CONCLUSIONS
  The present study provides preliminary evidence of the important role of variations in serotonin transmission related genes in determining clinical response to olanzapine. Considering previous studies, it can also be concluded that olanzapine and clozapine may have similar affinities to serotonin receptors.
authors.affiliation: Fundación Argibide, Pamplona. Division of Psychological Medicine, Institute of Psychiatry. London. United Kingdom. fundacionargibide.com
authors.forename: I
authors.initials: I
authors.lastname: Mata-Pastor
authors.forename: M J
authors.initials: MJ
authors.lastname: Arranz-Calderón
authors.forename: M
authors.initials: M
authors.lastname: Beperet-Urmeneta
authors.forename: F
authors.initials: F
authors.lastname: Pérez-Nievas
authors.forename: P
authors.initials: P
authors.lastname: Sham
authors.forename: R
authors.initials: R
authors.lastname: Kerwin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001569:Benzodiazepines; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012701:Serotonin / Q000378:metabolism*; D017367:Selective Serotonin Reuptake Inhibitors / Q000493:pharmacokinetics* / Q000627:therapeutic use
chemical_list: D001569:Benzodiazepines; D000077152:Olanzapine; D010890:Pirenzepine; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors